Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte (INCY) Up 3.3% Since Last Earnings Report: Can It Continue?

Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.

Incyte (INCY) Outperforms YTD: Will the Momentum Continue?

Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors

Data From Incyte's Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Activision Blizzard

CoStar Group

First Solar

Garmin

Moderna

Regeneron Pharmaceuticals

Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes their way.

7 Cash-Rich Stocks to Buy for Peace of Mind

More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting

Incyte reported 20% y/y product revenue growth in Q3 2022. Opzelura revenue grew $38 million y/y.

Incyte A Buy As Revenue From Opzelura Ramps

Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.

Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates

Incyte Corporation (NASDAQ:INCY ) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Christine Chiou - Head, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manager-North America Steven Stein - Executive Vice President and Chief Medical Officer Christiana Stamoulis - Executive Vice President and Chief Financial Officer Dash Dhanak - Executive Vice President and Chief Scientific Officer Conference Call Participants Salveen Richter - Goldman Sachs Tazeen Ahmad - Bank of America Jessica Fye - JPMorgan Vikram Purohit - Morgan Stanley Mara Goldstein - Mizuho Securities Leonid Timashev - RBC Capital Markets Matt Phipps - William Blair Kelsey Goodwin - Guggenheim Eva Privitera - Cowen Andrew Berens - SVB Securities Gavin Clark-Gartner - Evercore Kripa Devarakonda - Truist Operator Hello and welcome to the Incyte Third Quarter 2022 Financial and Corporate Update Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Incyte Corporation (INCY) Q3 2022 Earnings Call Transcript

Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Q3 Earnings and Revenues Miss Estimates

Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

e.l.f. Beauty

Hubbell

Monarch Casino & Resort

Invest in stocks like e.l.f. Beauty (ELF), Monarch Casino & Resort (MCRI), Incyte (INCY) and Hubbell (HUBB) at the moment for superb earnings growth.

4 Top-Rated Stocks to Buy Now for Solid Earnings Growth

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Incyte (INCY) Q3 Earnings Expected to Decline

Interactive Brokers

Lamb Weston Hlds

Williams

We have narrowed our search to five large-cap U.S. companies with strong potential for the rest of 2022. These are: IBKR, INCY, WMB, HUBB and LW.

A Bear Market Rally or Markets Forming a Solid Base: 5 Picks

Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte (INCY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Incyte (INCY) a Solid Growth Stock? 3 Reasons to Think "Yes"

Genmab - ADR

INCY vs. GMAB: Which Stock Is the Better Value Option?

Vertex Pharmaceuticals

One is doing much better than the other year to date, but they both have solid prospects ahead.

2 Cathie Wood Stocks That Are Beating the Market This Year

MONTREAL, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in combination with lenalidomide to ANVISA, the Brazilian health regulatory agency, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Names New Member to Its Board of Directors

Incyte Names New Member to Its Board of Directors

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Biotech has pulled back sharply after a summer rebound, but the niche continues to outperform the S&P 500. One mid-sized biotech company is looking forward to better earnings ahead with a decent pipeline of oncology and dermatology products.

Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart

Incyte (INCY) Down 2.9% Since Last Earnings Report: Can It Rebound?

Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement

News for Incyte Stock (INCY)